By Ginika Igboke
President Donald Trump used his State of the Union address Tuesday to press Congress to enshrine his prescription drug pricing initiative into law—an effort some lawmakers say could gain traction.
Rep. Byron Donalds praised the cost-saving potential of Trump’s Most-Favored-Nation Prescription Drug Pricing plan, saying it “really does matter to the American people.”
“Working with the president on codifying those things into law is important,” Donalds told reporters after the speech.
Spotlight on Drug Costs
During the address, Trump introduced Catherine Rayner, who described how she and her husband struggled with infertility and faced a $4,000 bill for IVF medication. Rayner said she was able to purchase the medication for $500 through TrumpRx.gov, a clearinghouse website for discounted drugs.
Under the voluntary policy framework, 15 pharmaceutical companies have agreed to offer their lowest available prices to Medicaid patients, introduce new drugs in the United States at their lowest international price, and in some cases sell medicines directly to consumers at reduced rates.
However, specific details of the agreements—including the scope and scale of price reductions—have not been publicly released.
Merith Basey, CEO of Patients for Affordable Drugs, said the current arrangements do not automatically lower prices across the entire health care system or apply broadly to high-cost medications. Still, she said congressional action could make a difference.
“If Congress codifies a strong, enforceable [Most-Favored Nation]-style policy into law, it could be a meaningful step toward bringing U.S. prices in line with those paid by other high-income countries,” Basey said in a Feb. 24 statement.
Broader Health Care Agenda
Trump’s broader “Great Health Care Plan,” announced Jan. 15, includes additional proposals that remain under consideration.
One proposal would create funded Health Savings Accounts (HSAs) for Affordable Care Act enrollees as an alternative to insurer subsidies. Eligible individuals could use the funds to pay insurance premiums or out-of-pocket expenses.
Another measure would require health care providers and insurers that accept Medicare or Medicaid to post prices prominently, expanding transparency requirements.
Sen. John Hoeven expressed optimism that the HSA proposal could receive bipartisan support.
“I think we could get bipartisan support and pass it, because it goes right to the people, and then they can decide how to spend it,” Hoeven said.
Jeremy Nighohossian, a senior fellow and economist at the Competitive Enterprise Institute, said key details remain unclear, including what “codifying” the Most-Favored-Nation policy would entail—whether it would formalize the TrumpRx.gov model, extend pricing terms to Medicare, or adopt a different mechanism.
Rep. Glenn Grothman said lawmakers have not yet seen full details and acknowledged the difficulty of passing drug price reforms, noting that many members of Congress receive campaign contributions from pharmaceutical companies.
“It would have to be through reconciliation, if we do anything,” Grothman said, referencing the budget process that allows certain legislation to pass with a simple majority in the Senate.
Cynthia Fisher, founder and chairman of Patient Rights Advocate, praised the administration’s transparency initiative, saying it would foster competition and help families avoid overcharges.
Democrats, however, dismissed the plan as insufficient. In a Feb. 24 statement, the Democratic National Committee said the proposal would not meaningfully reduce health care costs or lower drug prices.
The debate now turns to whether Congress will take up the president’s call to formalize the pricing initiative into law.
Original article
Comments